|1.||Miller, Duane D: 4 articles (07/2010 - 05/2008)|
|2.||Patil, Renukadevi: 4 articles (07/2010 - 05/2008)|
|3.||Geisert, Eldon E: 2 articles (07/2010 - 10/2008)|
|4.||Geisert, Eldon: 2 articles (05/2009 - 05/2008)|
|5.||Wang, XiangDi: 2 articles (05/2009 - 05/2008)|
|6.||Yates, Charles R: 2 articles (05/2009 - 05/2008)|
|7.||Ramagiri, Suma: 2 articles (05/2009 - 05/2008)|
|8.||Ma, Fei: 2 articles (05/2009 - 05/2008)|
|9.||Orr, William E: 2 articles (10/2008 - 05/2008)|
|10.||Falk, Marni J: 1 article (09/2011)|
|1.||Retinoblastoma (Glioblastoma, Retinal)
05/01/2009 - "Fast and sensitive liquid chromatography/electrospray mass spectrometry method to study ocular penetration of EDL-155, a novel antitumor agent for retinoblastoma in rats."
07/01/2010 - "EDL-155 appears to eliminate retinoblastoma cells by disrupting mitochondria and inducing autophagy. "
07/01/2010 - "EDL-155 appeared to destroy the retinoblastoma cells in vitro with an EC(50) of 9.1 micriM. "
07/01/2010 - "To evaluate the efficacy of EDL-155 in vivo, Y79-Luc retinoblastoma cells were injected into the vitreous cavity of newborn rats, followed by periocular injections of EDL-155 (20 mg/kg/day) or an equivalent dosage of saline. "
07/01/2010 - "In the retinoblastoma animal model, four doses of EDL-155 were delivered over 4 days, which was sufficient to see a significant decrease (P = 0.01) in viable intraocular tumors. "
05/01/2009 - "The assay was rapid, sensitive and robust enough to support EDL-155 ocular penetration studies in a rodent model of intraocular cancer. "
07/01/2010 - "Local delivery of EDL-155 may be an effective therapy for some types of ocular cancers."
07/01/2010 - "Seven of the 25 rats treated with EDL-155 had no detectable living tumor. "
05/01/2009 - "High local concentrations coupled with minimal systemic exposure supports further testing of EDL-155 as localized therapy for intraocular cancers."
10/01/2008 - "Animals treated with EDL-155 had significantly smaller tumors than did control animals treated with carrier solution. "
05/01/2008 - "In this study, peripheral and cerebrospinal fluid (CSF) pharmacokinetics in rats were determined to assess the drug developability of the novel THI EDL-155 for the treatment of glioma. "
10/01/2008 - "We observed anatomical changes in cultured glioma cells treated with EDL-155 that were consistent with selective destruction of mitochondria and the induction of autophagy. "
10/01/2008 - "The effect of EDL-155 was also tested in an animal model in which C6 glioma was transplanted into the brains of Sprague-Dawley rats. "
10/01/2008 - "Normal cultured rat astrocytes and C6 rat glioma were used as a differential screen to test the effects of EDL-155. "
10/01/2008 - "The selective killing of glioma in tissue culture and in the rat brain models indicates that EDL-155 has potential therapeutic value in treating this type of brain cancer."
|4.||Central Nervous System Neoplasms
|5.||Glioblastoma (Glioblastoma Multiforme)